MARKSANS PHARMA Q2 FY27 ; CONS NET PROFIT UP 44.77% AT ₹143.53 CR (YOY), DOWN 7.88% (QOQ)

REVENUE UP 30.50% AT ₹940.17 CR (YOY), UP 11.82% (QOQ) EBITDA UP 48.30% AT ₹214.29 CR (YOY), UP 0.59% (QOQ) MARGINS AT 22.79% VS 20.06% (YOY), 25.34% (QOQ)

MARKSANS PHARMA LIMITED

← Back to feed